2024

1. A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)

   Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 821-833

2. A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death

   Scientific reports, Vol. 14, Núm. 1, pp. 3000

3. CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions

   Gastric Cancer, Vol. 27, Núm. 4, pp. 747-759

4. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

   Therapeutic Advances in Gastroenterology, Vol. 17

5. Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study

   Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 727-733

6. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

   Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259

7. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

   Therapeutic Advances in Gastroenterology, Vol. 17

8. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance

   American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654

9. Endoscopic surveillance for familial intestinal gastric cancer in low-incidence areas: An effective strategy

   International Journal of Cancer, Vol. 154, Núm. 1, pp. 124-132

10. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

11. Gene content, phage cycle regulation model and prophage inactivation disclosed by prophage genomics in the Helicobacter pylori Genome Project

    Gut Microbes, Vol. 16, Núm. 1

12. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes

    Journal of Crohn's and Colitis, Vol. 18, Núm. 3, pp. 349-359

13. Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 750-758

14. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

15. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853

16. Prophylactic versus endoscopy-driven treatment of crohn's postoperative recurrence: A retrospective, multicentric, european study [porcse study]

    Journal of Crohn's and Colitis, Vol. 18, Núm. 8, pp. 1202-1214

17. Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study

    Journal of Clinical Medicine, Vol. 13, Núm. 2

18. Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease

    Digestive and Liver Disease, Vol. 56, Núm. 3, pp. 468-476

19. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

20. Stratified analyses refine association between TLR7 rare variants and severe COVID-19

    Human Genetics and Genomics Advances, Vol. 5, Núm. 4